U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07744646) titled 'Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis' on July 30.
Brief Summary: The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that Alpha-0261 is safe, and the secondary hypothesis is that Alpha-0261 is effective, as assessed by the proportion of participants achieving clinical remission per the complete modified Mayo score at Week 10.
Study Start Date: Aug. 03
Study Type: INTERVENTIONAL
Condition:
Ulcerative Colitis (UC)
Intervention:
DRUG: Alpha-0261
Drug: Alpha-0261 Oral, tablet
Recru...